Samsung/Biogen's Enbrel Biosimilar approaches EU
This article was originally published in Scrip
Executive Summary
Samsung Bioepis UK Ltd., the joint venture between Samsung Biologics and Biogen, has received a positive opinion from CHMP for Benepali, its biosimilar version of the blockbusting anti-inflammatory product Enbrel (etanercept).